How blood mutations affect cancer treatment outcomes and side effects
Impact of clonal hematopoiesis mutations on toxicity and outcomes following oncologic therapy
This study is looking at how certain DNA changes in the blood might affect how well cancer treatments work and their side effects in patients with solid tumors, especially those who have had radiation therapy, to help doctors better understand and improve care for their patients.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-10904692 on NIH RePORTER |
What this research studies
This research investigates the impact of clonal hematopoiesis (CH) mutations, which are acquired DNA mutations in the blood, on the toxicity and effectiveness of cancer treatments in patients with solid tumors. The study will analyze existing blood samples from patients who have undergone oncologic therapy, particularly focusing on those who have received radiation. By examining the relationship between these mutations and treatment outcomes, the research aims to identify potential biomarkers that could help predict adverse effects and improve patient care. This approach utilizes advanced DNA sequencing techniques and leverages data from large patient cohorts.
Who could benefit from this research
Good fit: Ideal candidates for this research are older individuals with solid tumors who have received oncologic therapies, especially radiation.
Not a fit: Patients without solid malignancies or those who have not undergone oncologic therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved cancer treatment strategies by identifying patients at higher risk for adverse effects and tailoring therapies accordingly.
How similar studies have performed: Previous research has indicated that understanding genetic mutations can significantly impact treatment outcomes, suggesting that this approach may yield valuable insights.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Nead, Kevin Thomas — University of Tx Md Anderson Can Ctr
- Study coordinator: Nead, Kevin Thomas
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.